Thus, the combination of serum DDR1 and tumour DDR1 levels with other monitoring methods, such as alpha fetoprotein (AFP), computed tomography (CT) or magnetic resonance imaging (MRI), might be helpful in forecasting recurrence. Here, AFP is linked to neoplasm.